Advertisement

Topics

TeneoBio licenses Ligand's OmniFlic antibody engineering technology

15:40 EDT 22 Sep 2016 | Elsevier Business Intelligence

TeneoBio Inc. licensed rights to use Ligand Pharmaceuticals Inc.'s OmniFlic transgenic rodent technology in its antibody discovery efforts.

Original Article: TeneoBio licenses Ligand's OmniFlic antibody engineering technology

NEXT ARTICLE

More From BioPortfolio on "TeneoBio licenses Ligand's OmniFlic antibody engineering technology"

Quick Search
Advertisement
 

Relevant Topics

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...